scholarly journals Development and validation of an HPLC‐MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run

2021 ◽  
Author(s):  
Ard Veelen ◽  
Robin Geel ◽  
Roy Schoufs ◽  
Yvo Beer ◽  
Leo M. Stolk ◽  
...  
Keyword(s):  
Human Plasma ◽  
Plasma Samples ◽  
Human Plasma Samples ◽  
Development And Validation

Development and Validation of a Chromatographic Ultraviolet Method for the Quantification of Isavuconazole in Human Plasma Samples

2018 ◽  
Vol 40 (4) ◽  
pp. 512-514 ◽  
Author(s):  
Valeria Cozzi ◽  
Sara Baldelli ◽  
Simone Castoldi ◽  
Emilio Clementi ◽  
Dario Cattaneo
Keyword(s):  
Human Plasma ◽  
Plasma Samples ◽  
Human Plasma Samples ◽  
Development And Validation

Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples

2014 ◽  
Vol 6 (22) ◽  
pp. 9108-9115 ◽  
Author(s):  
Elodie Odore ◽  
François Lokiec ◽  
Sophie Weill ◽  
J. Kay Noel ◽  
Patrice Herait ◽  
...  
Keyword(s):  
Quantitative Analysis ◽  
Human Plasma ◽  
Pharmacokinetic Study ◽  
Plasma Samples ◽  
Human Plasma Samples ◽  
Development And Validation

Development and validation of a rapid and robust UPLC-MS/MS method for quantification of a novel bromodomain inhibitor, OTX015 and its application to a pharmacokinetic study.

New Analytical Method for Simultaneous Analysis of Losartan and E-3174 by HPLC in Human Plasma: Application in Pharmaceutical Science

2020 ◽  
Vol 16 (8) ◽  
pp. 979-987
Author(s):  
Edgar Alejandro de Leon-Diaz de Leon ◽  
Antonio Gordillo-Moscoso ◽  
Úrsula Medina ◽  
Ángel Antonio Vertiz Hernández ◽  
Rafael Almendra-Pegueros ◽  
...  
Keyword(s):  
Human Plasma ◽  
Analytical Method ◽  
Compartmental Model ◽  
Pharmacokinetic Profile ◽  
Therapeutic Drug ◽  
Plasma Samples ◽  
Simultaneous Quantification ◽  
Human Plasma Samples ◽  
Development And Validation

Background: Losartan, one of the most frequently used drugs in Heart Failure (HF) treatment, could be modified for its bioavailability (BA) by generic formulations and other factors. Hence, the importance of therapeutic drug monitoring. Objective: Development and validation of a simplified analytical method using HPLC for simultaneous quantification of losartan and E-3174 in human plasma samples. The method was tested for determining the pharmacokinetics parameters of HF patients. Methods: Analytical conditions were optimized using a C18 column (4.6 X 50 mm, 3 μm. Thermo Scientific) at 25ºC. Conditions of mobile phase: a phosphate buffer (0.01M), adjusted to pH 2.5 with phosphoric acid (1M) and Acetonitrile (60:40 v/v). The flow rate was maintained at 1.2 mL/min, on a running time of 5 min and a sample injection volume of 50 μL. Absorbance for measurement of losartan and E-3174 was 200 nm. Pharmacokinetics profiles were determined with Phoenix Win- Nonlin 8.1 software in a non-compartmental model. Results: Analytical method developed and validated in this work is precise and accurate for simultaneous determination of losartan and E-3174 in human plasma samples in a range of 0.02 -10 μg/mL. In HF subjects, lower Tmax and higher Cmax for losartan and E-3174 patent than generic formulation were observed, which can be translated into less biological effect and more time to present it by the generic drug. Conclusion: The pharmacokinetic profile is dependent on the type of formulation studied (generic/ patent) hence the importance of conducting evaluations in our patients to ensure that the expected therapeutic effect is achieved with treatment administered.

Sign in / Sign up

Export Citation Format

Share Document